These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 22398057

  • 1. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
    Ogawa K, Matsumoto T, Esaki M, Torisu T, Iida M.
    J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
    [Abstract] [Full Text] [Related]

  • 2. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 3. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
    Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska-Jarosińska M.
    World J Gastroenterol; 2014 Jun 14; 20(22):7019-26. PubMed ID: 24944497
    [Abstract] [Full Text] [Related]

  • 4. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.
    J Crohns Colitis; 2013 Oct 14; 7(9):736-43. PubMed ID: 23200919
    [Abstract] [Full Text] [Related]

  • 5. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.
    Scand J Gastroenterol; 2017 Oct 14; 52(10):1086-1092. PubMed ID: 28622097
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A.
    Dig Liver Dis; 2014 Aug 14; 46(8):695-700. PubMed ID: 24893686
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.
    Gut; 2014 Jun 14; 63(6):919-27. PubMed ID: 23878167
    [Abstract] [Full Text] [Related]

  • 12. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, Wikström AC, Eberhardson M.
    J Crohns Colitis; 2014 Aug 14; 8(8):881-9. PubMed ID: 24486178
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
    Detková Z, Kupcová V, Príkazská M, Turecký L, Weissová S, Jahnová E.
    Physiol Res; 2003 Aug 14; 52(1):95-100. PubMed ID: 12625813
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R, Stüber E, Häsler R, Nikolaus S, Kühbacher T, Hampe J, Bewig B, Schreiber S, Arlt A.
    J Crohns Colitis; 2012 May 14; 6(4):464-9. PubMed ID: 22398062
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 19. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct 01; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 20. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T.
    J Crohns Colitis; 2013 Dec 01; 7(12):950-7. PubMed ID: 23411006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.